Human factor X ( DrugBank: Factor X )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
288自己免疫性後天性凝固因子欠乏症6

288. 自己免疫性後天性凝固因子欠乏症


臨床試験数 : 206 薬物数 : 231 - (DrugBank : 28) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 21
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-003093-98-GB
(EUCTR)
24/02/201502/01/2013The purpose of this study is to look at how well FACTOR X works in preventing bleeding when taken regularly in children aged under 12 years old, over a period of 6 months. The study will also look at how safe FACTOR X is by closely following the subjects progress during the study.A Phase III Open, Multicentre Study to Confirm the Safety, Pharmacokinetics and Efficacy of BPL’s High Purity Factor X in the Prophylaxis of Bleeding in Factor X Deficient Children Under the Age of 12 Years Factor X Deficiency;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]Product Name: Human factor X
Product Code: FACTOR X
INN or Proposed INN: Human Coagulation Factor X
Other descriptive name: FACTOR X
Bio Products Laboratory LimitedNULLNot RecruitingFemale: yes
Male: yes
8Phase 3Turkey;United Kingdom
2EUCTR2009-015086-31-ES
(EUCTR)
03/05/201227/02/2012A study for people with coagulation factor X deficiency, to assess the effectiveness and safety of a high purity factor X concentrate for people having surgery.Ten03: A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL’s High Purity Factor X in the treatment of the Factor X Deficient Subjects Undergoing Surgery Factor X Deficiency;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]Product Name: Human factor X
Product Code: FACTOR X
Other descriptive name: FACTOR X
Bio Products Laboratory LimitedNULLNot RecruitingFemale: yes
Male: yes
10Phase 3United States;Spain;Turkey;Germany;United Kingdom;India
3EUCTR2009-011145-18-DE
(EUCTR)
21/09/201001/04/2010A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency - A PK study of BPL's FX in patients with FX deficiencyA Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency - A PK study of BPL's FX in patients with FX deficiency Factor X deficiency
MedDRA version: 12.1;Level: LLT;Classification code 10052474;Term: Factor X deficiency
Product Name: Human factor X
Product Code: FACTOR X
Other descriptive name: Human factor X
Bio Products Laboratory LimitedNULLNot RecruitingFemale: yes
Male: yes
16Phase 3Spain;Germany;United Kingdom
4EUCTR2009-015086-31-GB
(EUCTR)
16/03/201017/03/2010A study for people with coagulation factor X deficiency, to assess the effectiveness and safety of a high purity factor X concentrate for people having surgery.Ten03: A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL’s High Purity Factor X in the treatment of the Factor X Deficient Subjects Undergoing Surgery Factor X Deficiency;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]Product Name: Human factor X
Product Code: FACTOR X
Other descriptive name: FACTOR X
Bio Products Laboratory LimitedNULLNot RecruitingFemale: yes
Male: yes
10Phase 3United States;Spain;Turkey;Germany;United Kingdom;India
5EUCTR2009-011145-18-ES
(EUCTR)
07/12/200902/10/2009A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.Estudio de fase III, multicéntrico y abierto que investiga la farmacocinética, la seguridad y la eficacia del factor X de alta pureza de BPL en el tratamiento de la deficiencia del factor X grave y moderada. - A PK study of BPL's FX in patients with FX deficiencyA Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency.Estudio de fase III, multicéntrico y abierto que investiga la farmacocinética, la seguridad y la eficacia del factor X de alta pureza de BPL en el tratamiento de la deficiencia del factor X grave y moderada. - A PK study of BPL's FX in patients with FX deficiency Factor X deficiency.Deficiencia de Factor X
MedDRA version: 12.0;Level: LLT;Classification code 10052474;Term: Factor X deficiency
Product Name: Human factor X
Product Code: FACTOR X
Other descriptive name: Human factor X
Bio Products LaboratoryNULLNot RecruitingFemale: yes
Male: yes
16Phase 3Spain;Germany;United Kingdom
6EUCTR2009-011145-18-GB
(EUCTR)
02/11/200924/09/2009A study for people with severe and moderate coagulation factor X deficiency, to assess the effectiveness and safety of a high purity factor X concentrate, and how it is handled by the body.A Phase III Open, Multicentre Study to Investigate the Pharmacokinetics, Safety and Efficacy of BPL's High Purity Factor X in the Treatment of Severe and Moderate Factor X Deficiency - A PK study of BPL's FX in patients with FX deficiency Factor X deficiency
MedDRA version: 14.1;Level: PT;Classification code 10052474;Term: Factor X deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: Human factor X
Product Code: FACTOR X
INN or Proposed INN: Human coagulation Factor X
Other descriptive name: Human factor X
Bio Products Laboratory LtdNULLNot RecruitingFemale: yes
Male: yes
16Phase 3United States;Spain;Turkey;Germany;United Kingdom